Eisai Co., Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ESAIY Over the counter 2830 www.eisai.co.jp

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eisai Co., Ltd.

Can Biogen's New Drugs Revive Growth Amid Legacy Sales Slump? - Jun 26th, 2026 6:20 am
Beren Therapeutics Secures $300M Financing to Support the Potential Commercial Launch of Adrabetadex and Long-Term Care Initiatives for Infantile-Onset Niemann-Pick Disease, Type C - Jun 10th, 2026 7:00 am
Eisai and CaringKind Launch New Initiative to Address Mealtime and Nutrition Needs for People Living with Alzheimer's Disease and Related Dementias - Jun 1st, 2026 5:00 am
BioArctic's partner Eisai presents sales simulation of potential future sales of Leqembi® at its Investor Relations Day - May 25th, 2026 1:37 am
How Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value Outlook - May 21st, 2026 6:17 am
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight - May 20th, 2026 11:00 am
BioArctic Interim Report for the period January - March 2026 - May 20th, 2026 1:37 am
Eisai projects Leqembi® revenue to total JPY 143.5 billion for fiscal year 2026 (April 2026 - March 2027) - May 15th, 2026 12:59 am
Biogen Moves Alzheimer’s Drug to Late-Stage Trials. Wall Street Thinks It’s a Mistake. - May 14th, 2026 12:30 pm
Merck Stock Down 7% in a Month: Should Investors Hold or Exit? - May 11th, 2026 9:18 am
Eisai (TSE:4523) Valuation Check After Recent Share Price Pullback And LEQEMBI Growth Story - May 9th, 2026 4:14 am
Leqembi® Iqlik™ PDUFA date updated to August 24 in the U.S. - May 8th, 2026 12:50 am
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease - May 8th, 2026 12:30 am
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease - May 8th, 2026 12:30 am
Angelini to buy Catalyst in $4B play for rare neuro drugs - May 7th, 2026 5:20 am
Nuvation Bio Q1 Earnings Call Highlights - May 4th, 2026 7:10 pm
MRK Down as Triplet Therapy Fails to Meet Goal in Kidney Cancer Study - Apr 22nd, 2026 10:14 am
Total Investment of Approx. USD 8.5 Million in Malaria and NTD R&D Projects With Partners Including MMV, GSK, Tanabe Pharma, Eisai and DNDi - Apr 21st, 2026 8:00 pm
Why Merck (MRK) Shares Are Trading Lower Today - Apr 21st, 2026 6:53 pm
Why Dow Jones Stock Merck Skidded 4% — And Boosted A Key Rival - Apr 21st, 2026 2:15 pm